Forbion
Venture capitalNaarden · Pre-Seed–Late Stage · 24 people tracked
Also known as FCPM III SERVICES B.V. · FORBION NORTH AMERICA LLC
Investment thesis
Forbion invests in groundbreaking biotech and other sustainable solutions that improve the health of people and the planet, structured around human health and planetary health themes. The firm integrates ESG principles into its investments, emphasizing patient impact, societal benefits, and sustainability. It manages a family of funds spanning venture, growth, and bioeconomy strategies, backing companies working on rare disease therapies, novel treatments, and sustainable technologies such as plant-based metal extraction.
Source: firm website, verified Aug 3, 2026.
Team · 24 people
from the firm's website & public directories
What they invest in
from 12 of 15 portfolio companiesBiotech ×10Medical Devices ×4Healthtech ×2AI & Machine Learning ×1Cleantech ×1Cybersecurity ×1Deep Tech ×1Enterprise Software ×1
HQs:United States×5Switzerland×1Colombia×1United Kingdom×1
Investments · 15 tracked
founders shown can be your intro pathDyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Lawrence Klein, Ph.D.(Director)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)David Lubner(Director)Edward Hurwitz(Director)Dirk Kersten(Director)
Board seatDirk Kersten· per SEC Form D · $115.7M raise · filed Aug 2020
BiotechRedwood City, US
Kristopher Hanson(Executive Officer)Timothy Garnett(Director)George Pavlov(Director)Peter Bisgaard(Director)Erin Foff(Executive Officer)Anatol Kreitzer(Executive Officer)
Board seatNanna Luneborg· per SEC Form D · $372.4M raise · filed Jul 2025
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)
HealthtechCambridge, US
William Kelly(Chief Financial Officer and Secretary of Issuer)Kapil Dhingra(Director)Joseph Slattery(Director)Joseph Boystak(Director)Geert-Jan Mulder(Director)Thomas McLain(Chief Executive Officer and Director of Issuer)
Board seatGeert-Jan Mulder· per SEC Form D · $2.2M raise · filed Jul 2015
Stevenage, Hertfordshire
Board seatWouter Joustra· per SEC Form D · $148M raise · filed Apr 2021
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
Zach Scheiner(Director)William Daley Bonificio(Executive Officer, Promoter)Megan Krench(Director)Stephen Basil Thomas(Executive Officer, Promoter)Dmitrij Hristodorov(Director)Naveen Manu Daryani(Executive Officer, Director, Promoter)
Board seatDmitrij Hristodorov· per SEC Form D
BiotechMontreal
Debra Liebert(Director)Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)
Board seatMarco Boorsma· per SEC Form D · $6.9M raise · filed Jul 2017
BiotechScotch Plains, US
STEPHEN BASIL THOMAS(Executive Officer, Director, Promoter)WILLIAM DALEY BONIFICIO(Executive Officer, Promoter)NAVEEN MANU DARYANI(Executive Officer)
BoardANDREW LEVIN(Director)
Board seatWouter Joustra· per SEC Form D · $100M raise · filed Sep 2024
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)
A fully integrated gene therapy company developing innovative therapeutics including vectorized antibodies for CNS and somatic disorders, with focus on muscle diseases.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 5
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Forbion BioEconomy Fund I Co?peratief U.A.LPs: California Public Employees' Retirement System | 2024 | — | — | 0.90x | 0.00x |
| Forbion Growth Opportunities Fund III Co?peratief U.A.LPs: California Public Employees' Retirement System | 2024 | — | — | 0.65x | 0.07x |
| Forbion Ventures Fund VII Co?peratief U.A.LPs: California Public Employees' Retirement System | 2024 | — | — | 0.85x | 0.01x |
| Forbion Growth Opportunities Fund II Cooperatief U.A.LPs: California Public Employees' Retirement System | 2023 | — | — | 1.64x | 1.01x |
| Forbion Ventures Fund VI Cooperatief U.A.LPs: California Public Employees' Retirement System | 2023 | — | — | 1.34x | 0.34x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does Forbion invest at?
- Forbion invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Forbion focus on?
- Forbion focuses on AgTech, Biotech, Cleantech, Climate Tech, Healthtech, Impact & Social Good, Medical Devices.
- Where is Forbion located?
- Forbion is headquartered in Naarden, NL.
Media · Podcasts & interviews
featuring the teamBIO-Europe® 2015: Interview with Sander Slootweg, Forbion Capital Partners
EBD Group · Sander Slootweg
Message by Olivér Várhelyi on the occasion of the European Life Sciences Coalition
Forbion
Forbion 2nd Annual Excellence Roundtable: The future of innovation in rare diseases
Forbion
From Bench to Boardroom: The 2nd Annual Cambridge–Forbion Roundtable
Forbion
Forbion Patient Perspective Series | Episode 1 - What ALS can't take from Marcel
Forbion
Special Event with the Cambridge Judge Business School
Forbion
Images
Co-investors · 39
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
BioGeneration Ventures is a venture capital firm that invests in early-stage biotech companies in Europe, with a focus on healthcare innovations.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Longwood Fund is a Boston-based venture firm focused on discovering and building science-based companies, with a team spanning doctors, scientists, entrepreneurs, and investors.
Seroba is a Dublin-based life sciences venture capital firm investing in early-stage biotech and medtech companies developing new therapeutics and medical devices.
Founders Fund is a venture capital firm that invests in companies building transformative technologies across defense, space, data analytics, and other frontier sectors.
▶27 more co-investors
New Enterprise Associates (NEA)F-Prime Capital PartnersPolaris PartnersUS Venture PartnersGeneral AtlanticOrbiMedHTGFEQT Life Sciences5AM VenturesCambridge Innovation CapitalDomain AssociatesThird Rock VenturesPivotal bioVenture PartnersPfizer Venture InvestmentsKurma PartnersAccess IndustriesAndera PartnersNextech InvestSeventure PartnersYsios CapitalAdvent Life SciencesAlta PartnersRiverVest VentureRTW Investments L.P.Red Tree Venture4see VenturesArcus Ventures
Firms observed investing alongside Forbion, from public investor directories. Shared companies are the overlap with Forbion's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Innovestor is a Nordic investment group operating across venture capital, life science, real estate, energy storage, and corporate venturing platforms, and is among the most active early-stage investors in the region.
MDI Ventures is the corporate venture capital arm of Indonesia's Telkom Group, investing in technology startups and emphasizing measurable social and environmental impact alongside financial returns.
UntroD Capital is a deep-tech-focused investment firm that backs research-and-development-driven startups whose innovative technologies address challenges facing the planet and humanity, an approach it terms 'Real Tech'.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.